245 related articles for article (PubMed ID: 36001163)
1. Immunotherapy for hepatocellular carcinoma.
Zhou M; Liu B; Shen J
Clin Exp Med; 2023 Jul; 23(3):569-577. PubMed ID: 36001163
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
6. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of hepatocellular carcinoma: recent progress and new strategy.
Li J; Xuan S; Dong P; Xiang Z; Gao C; Li M; Huang L; Wu J
Front Immunol; 2023; 14():1192506. PubMed ID: 37234162
[TBL] [Abstract][Full Text] [Related]
8. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go.
Wang K; Wang C; Jiang H; Zhang Y; Lin W; Mo J; Jin C
Front Immunol; 2021; 12():792781. PubMed ID: 34975896
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.
Mandlik DS; Mandlik SK; Choudhary HB
World J Gastroenterol; 2023 Feb; 29(6):1054-1075. PubMed ID: 36844141
[TBL] [Abstract][Full Text] [Related]
10. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP; Khakoo SI
World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
[TBL] [Abstract][Full Text] [Related]
12. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.
Wei H; Dong C; Li X
J Clin Transl Hepatol; 2024 Apr; 12(4):389-405. PubMed ID: 38638377
[TBL] [Abstract][Full Text] [Related]
14. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?
Obeid JM; Kunk PR; Zaydfudim VM; Bullock TN; Slingluff CL; Rahma OE
Cancer Immunol Immunother; 2018 Feb; 67(2):161-174. PubMed ID: 29052780
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
17. [Progress in immunotherapy for hepatocellular carcinoma].
Shen Z; Li M; Bai S; Yang Q; Zhang F; Tang M; Guo J; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2326-2338. PubMed ID: 31880139
[TBL] [Abstract][Full Text] [Related]
18. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle.
Sukowati C; Cabral LKD; Tiribelli C
Ann Hepatol; 2022; 27(5):100740. PubMed ID: 35809835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
